INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10779540
Filing Date		2004-02-13
First Named Inventor	Onur	G. Guleryuz
Art Unit		2624
Examiner Name	Bhav	vesh M. Mehta
Attorney Docket Numb	er	AP183HO

				U.S.	PATENTS	Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	6587592	B2	2003-07-01	Georgiev, et al.			
	2	5081690		1992-01-14	Tan, Hin-Leong			
	3	6862366	B2	2005-03-01	Bhattacharjya, Anoop			
	4	6636565	B1	2003-10-21	Km, Eung Tae			
	5	6643406		2003-11-04	Hajjahmad, et al.			
	6	6549674		2003-04-15	Chui, et al.			
	7	6611627		2003-08-26	LaRossa, et al.			
	8	6377280		2002-04-23	Acharya, et al.			
If you wis	h to ac	l dd additional U.S. Pate	nt citatio	n information p	lease click the Add button.	Add		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Publication Number

Examiner Cite

Everniner Cite

1

Examiner Signature

Initials* No

Initial* No Kind Publication

Code¹ Date

publisher, city and/or country where published.

Application Number		10779540
Filing Date		2004-02-13
First Named Inventor Onur		G. Guleryuz
Art Unit		2624
Examiner Name	Bhavesh M. Mehta	
Attorney Docket Number		AP183HO

Date Considered

Remove Pages Columns Lines where

Figures Appear

Relevant Passages or Relevant

Т5

	1								
If you wis	h to a	dd additional U.S. Publ	ished Applicati	on citatio	n information	please click the Add b	utton. Add		
FOREIGN PATENT DOCUMENTS Remove									
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code4	Publication Date	Name of Patentee of Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	т .	
	1								
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
	NON-DATENT LITERATURE DOCUMENTS Remove								

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

U.S. PATENT APPLICATION PUBLICATIONS

Name of Patentee or Applicant

of cited Document

If you wish to add additional non-patent literature document citation information please click the Add button Add

FYAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO. Standard ST 3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 2 Applicant is to place a check mark here if English language translation is attached

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10779540
Filing Date		2004-02-13
First Named Inventor	Onur G. Guleryuz	
Art Unit		2624
Examiner Name	Bhavesh M. Mehta	
Attorney Docket Number		AP183HO

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 and 1.	98 to make the a	appropriate selection(s):
---------------	-----------------	------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Daniel A. Ratoff/	Date (YYYY-MM-DD)	2006-06-12				
Name/Print	Daniel A. Ratoff	Registration Number	54389				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Bot 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.